Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5845119 | 0.98 | EPHX2 (0.64) | EPHX2TSHRKDM4EHTTMAOA | |
| SCHEMBL23641349 | 0.98 | EPHX2 (0.64) | EPHX2TSHRKDM4EHTTMAOA | |
| SCHEMBL19542362 | 0.98 | EPHX2 (0.64) | EPHX2TSHRKDM4EHTTMAOA | |
| SCHEMBL22623764 | 0.86 | TSHR (0.53) | EPHX2TSHRKDM4EHTTMAOA | |
| SCHEMBL11169825 | 0.86 | TSHR (0.53) | EPHX2TSHRKDM4EHTTMAOA | |
| SCHEMBL16111819 | 0.85 | EPHX2 (0.73) | EPHX2TSHRKDM4EMAPTALDH1A1 | |
| SCHEMBL16111818 | 0.85 | EPHX2 (0.73) | EPHX2TSHRKDM4EMAPTALDH1A1 | |
| SCHEMBL11172424 | 0.84 | TSHR (0.52) | EPHX2TSHRKDM4EHTTMAOA | |
| SCHEMBL4653040 | 0.82 | EPHX2 (0.69) | EPHX2TSHRMAPTALDH1A1 | |
| SCHEMBL13295596 | 0.82 | EPHX2 (0.69) | EPHX2TSHRMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002013812-A1 | METHODS FOR TREATING INFLAMMATORY DISEASES | PERSHADSINGH HARRIHAR A (US) | 2002-02-21 | — | — | WO | claimed |
| US-20020019344-A1 | Methods of preventing allograft rejection | PERSHADSINGH HARRIHAR A (US) | 2002-02-14 | — | — | US | claimed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| EP-1931337-B1 | PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2013-10-23 | — | — | EP | disclosed |
| US-8119602-B2 | Administration of HCV protease inhibitors in combination with food to improve bioavailability | SCHERING CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-7902157-B2 | Spirocyclic azetidin(one); e.g. 2,7-diazaspiro[3.5]nonan-1-one; T-type calcium channel blockers; Niemann-Pick C1-like (NPC1L1) antagonists | SCHERING CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| US-7884080-B2 | Administering an azetidinone compound for treating a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease; T-type calcium channel blocking agent, an antagonist of TRPV1, an agonist of TRPV1, of GPR119, antagonist of NPCL1 | SCHERING PLOUGH CORPORATION (US) | 2011-02-08 | — | — | US | disclosed |
| US-20100291034-A1 | COMBINATIONS OF HCV PROTEASE INHIBITOR(S) AND CYP3A4 INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2010-11-18 | — | — | US | disclosed |
| US-7638526-B2 | Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7612058-B2 | Methods for inhibiting sterol absorption | SCHERING CORPORATION (US) | 2009-11-03 | — | — | US | disclosed |
| EP-2091534-A1 | AZETIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2000078313-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000078314-A1 | PROCESS FOR MAKING ARYLTHIAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000078312-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | disclosed |
| EP-1040102-A1 | ARYLTHIAZOLIDINEDIONE DERIVATIVES | Merck & Co., Inc. (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-1040102-A1 | ARYLTHIAZOLIDINEDIONE DERIVATIVES | Merck & Co., Inc. (US) | 2000-10-04 | — | — | EP | disclosed |
| US-6008237-A | POTENT AGONISTS OF PEROXIDSOME PROLIFERATOR ACTIVATED RECEPTOR; FOR CONTROLLING OR PREVENTING OF DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, OBESITY, VASCULAR RESTENOSIS | MERCK & CO., INC. (US) | 1999-12-28 | — | — | US | disclosed |
| US-6008237-A | POTENT AGONISTS OF PEROXIDSOME PROLIFERATOR ACTIVATED RECEPTOR; FOR CONTROLLING OR PREVENTING OF DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, OBESITY, VASCULAR RESTENOSIS | MERCK & CO., INC. (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1999032465-A1 | ARYLTHIAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032465-A1 | ARYLTHIAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | EPHX2 3576/4885TSHR 2355/4885KDM4E 4338/4885 |
| US-20100291034-A1 | COMBINATIONS OF HCV PROTEASE INHIBITOR(S) AND CYP3A4 INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | CYP3A43, CYP3A4, CYP3A7 | EPHX2 1019/4885TSHR 4198/4885KDM4E 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.